GT Biopharma, Inc.
GTBP · XNASCIK 109657fmd_0F2B69HFF5E3MBJKMP4PZEFDHVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | 0 | 0 | – | – | – | – | – |
| Cost of revenue | 0 | 0 | – | – | – | – | – | – | – | – |
| Gross profit | 0 | 0 | – | – | – | – | – | – | – | – |
| Research and development | 1 | 1 | 9 | 2 | 0 | 10 | 9 | 6 | 6 | 3 |
| Selling, general and administrative | 8 | 135 | 12 | 10 | 6 | 48 | 12 | 7 | 9 | 9 |
| Total operating expenses | 9 | 136 | 250 | 16 | – | 58 | 21 | 14 | – | – |
| Operating income | (9) | (136) | (250) | 16 | (7) | (58) | (21) | (14) | (14) | (12) |
| Interest expense | 7 | 9 | 9 | (2) | (3) | 1 | 0 | 0 | – | 0 |
| Other non-operating income (expense) | 19 | (9) | (9) | 23 | (22) | (0) | 0 | 6 | 1 | (16) |
| Income before taxes | 10 | (144) | (259) | (39) | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Net income from continuing operations | 10 | (144) | (259) | (39) | – | – | – | – | – | – |
| Net income | 10 | (144) | (259) | (39) | (28) | (58) | (21) | (8) | (13) | (28) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (13) | (34) |